Informazioni cliniche
Le zecche possono trasmettere all'uomo diversi agenti infettivi virali, batterici e parassitari durante il pasto di sangue. Oltre alla Borrelia, che causa la borreliosi di Lyme, la più frequente malattia trasmessa dalle zecche nell'emisfero settentrionale, la gamma di agenti patogeni comprende il virus della TBE, il virus della febbre di Crimea-Congo, l'Anaplasma, la Rickettsia, la Babesia, l'Ehrlichia e la Coxiella. A seconda dell'agente patogeno, le infezioni da zecche possono provocare vari sintomi clinici, conivolgendo ad esempio la pelle, le articolazioni, i muscoli, gli organi interni e il sistema nervoso centrale. Il decorso della malattia varia da asintomatico o subclinico a grave e pericoloso per la vita. Poiché esistono vaccini solo per alcuni dei patogeni trasmessi dalle zecche, la profilassi dell‘esposizione è la misura di protezione più efficace.
Diagnostica
Laboratory diagnostics of tick-borne infections are based on direct and indirect detection methods. Direct procedures include e.g. blood smears, pathogen cultures or PCR-based tests, while indirect detection is mainly based on the detection of specific antibodies against the respective pathogen in patient serum, plasma or CSF. Detection of antibodies is the most important laboratory diagnostic method in cases where it is difficult to obtain suitable sample materials for direct detection, or the amount of pathogen in the sample is too low. For antibody determination in cases of suspected tick-borne infection, EUROIMMUN offers a wide range of serological test systems, including ELISAs, ChLIAs, immunofluorescence tests (IIFT), immunoblots and EUROMicroblots, miniaturised immunoblots in microplate format.
La diagnostica di laboratorio delle infezioni da zecche si basa su metodi di rilevamento diretti e indiretti. Le procedure dirette comprendono, ad esempio, esami su strisci di sangue, colture di patogeni o test basati sulla PCR, mentre il rilevamento indiretto si basa principalmente sulla rilevazione di anticorpi specifici contro il rispettivo patogeno nel siero, nel plasma o nel liquor del paziente. La determinazione degli anticorpi è il metodo diagnostico di laboratorio più importante nei casi in cui è difficile ottenere materiali di campionamento adatti per la rilevazione diretta o la quantità di patogeno nel campione è troppo bassa. Per la determinazione degli anticorpi nei casi di sospetta infezione da zecche, EUROIMMUN offre un'ampia gamma di sistemi di test sierologici, tra cui ELISA, ChLIA, test di immunofluorescenza (IIFT), immunoblots ed EUROMicroblots, immunoblots miniaturizzati in formato micropiastra.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
Anti-TBE Virus CSF ELISA 2.0 (IgG) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | 5/25/50/100/175/230 U/ml | IgG |
96 x 01 |
EI 2661-9601-2L G |
| ELISA |
Anti-TBE Virus CSF ELISA 2.0 (IgM) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | IgM |
96 x 01 |
EI 2661-9601-2L M | |
| ELISA |
CSQ pair of controls anti-Borrelia (IgG) |
IgG |
02 x 20 |
CK 2132-0220-L G | |||
| ELISA | Anti-Borrelia CSF ELISA 2.0 (IgM) |
antigen-coated microplate wells |
TBE viral proteins | IgM |
96 x 01 |
EI 2132-9601-2L M | |
| ELISA |
CSF: Anti-Borrelia plus VlsE ELISA (IgG) Sample type: CSF/serum pair |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii PLUS recombinant VlsE from Borrelia burgdorferi sensu stricto |
5/25/50/100/175/230 U | IgG |
96 x 01 |
EI 2132-9601-L G |
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT (IgG) (p18, p19, p20, p21, p58, OspC (p25), p39, p83, LBb, LBa, VlsE Bg, VlsE Bb, VlsE Ba separately) |
EUROLINE | IgG IgG IgG |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001 G DN 2131-3201 G DN 2131-5001 G |
||
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT (IgM) (OspC Bg native, OspC Bb native, OspC Ba native, p39, VlsE Bb separately) |
EUROLINE | IgM IgM IgM |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001 M DN 2131-3201 M DN 2131-5001 M |
||
| ELISA | Anti-Crimean-Congo fever virus(CCHFV) ELISA (IgG) |
antigen-coated microplate wells |
recombinant protein from CCHFV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 279a-9601 G |
| ELISA | Anti-Crimean-Congo fever virus(CCHFV) ELISA (IgM) |
antigen-coated microplate wells |
recombinant protein from CCHFV |
semi-quantitative | IgM |
96 x 01 |
EI 279a-9601 M |
| IIFT | TBE virus (TBEV) |
infected and non- infected cells (2 BIOCHIPs per field) |
EU 14 | IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2661-1005 G FI 2661-1005 M FI 2661-1010 G FI 2661-1010 M |
|
| IIFT |
Flavivirus Mosaic 1 TBE virus (TBEV) West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) |
4 BIOCHIPs per field: infected cells infected cells infected cells infected cells |
EU 14 EU 14 EU 14 EU 14 |
IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2661-1005-1 G FI 2661-1005-1 M FI 2661-1010-1 G FI 2661-1010-1 M |
|
| IIFT |
Flavivirus Profile 2 upper row: TBE virus (TBEV) West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) bottom row: Dengue virus types 1 - 4 (DENV) |
infected cells infected cells infected cells infected cells infected cells |
EU 14 EU 14 EU 14 EU 14 EU 14 |
IgG IgM IgG IgM |
10 x 05 10 x 05 20 x 05 20 x 05 |
FI 2661-1005-2 G FI 2661-1005-2 M FI 2661-2005-2 G FI 2661-2005-2 M |
|
| ELISA |
Anti-TBE Virus ELISA 2.0 (IgG) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | IgG |
96 x 01 |
EI 2661-9601-2 G | |
| ELISA |
Anti-TBE Virus ELISA 2.0 (IgM) tick-borne encephalitis virus |
antigen-coated microplate wells |
semi-quantitative | IgM |
96 x 01 |
EI 2661-9601-2 M | |
| IIFT |
EUROPLUS Borrelia afzelii Borrelia burgdorferi (USA) OspC antigen VlsE antigen |
4 BIOCHIPs per field: bacterial smear bacterial smear OspC BIOCHIPs VlsE BIOCHIPs |
B. afzelii B. burgd. (USA) B. burgdorferi recombinant |
IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2136-1005-1 G FI 2136-1005-1 M FI 2136-1010-1 G FI 2136-1010-1 M |
|
| ELISA |
Anti-Borrelia ELISA (IgM) whole antigen extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii |
2/20/200 RU/ml | IgM |
96 x 01 |
EI 2132-9601 M |
| ELISA |
Anti-Borrelia plus VlsE ELISA (IgG) whole antigen extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii plus recombinant VlsE |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii plus recombinant VlsE from Borrelia burgdorferi sensu stricto |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2132-9601-2 G |
| ELISA | Anti-Coxiella burnetii Phase 1 ELISA (IgG) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the chronical phase |
semi-quantitative | IgG |
96 x 01 |
EI 217a-9601-1 G |
| ELISA | Anti-Coxiella burnetii Phase 2 ELISA (IgG) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the acute phase |
semi-quantitative | IgG |
96 x 01 |
EI 217a-9601-2 G |
| ELISA | Anti-Coxiella burnetii Phase 2 ELISA (IgM) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the acute phase |
semi-quantitative | IgM |
96 x 01 |
EI 217a-9601-2 M |
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for Borrelia |
IgG |
05 x 07 |
CL 2131-0507 G | |||
| EUROLINE |
positive control serum: IgM, human, 50x concentrated for Borrelia |
IgM |
05 x 07 |
CL 2131-0507 M | |||
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT-adv (IgM) (OspC-adv Bsp, OspC-adv Bg, OspC-adv Bb, OspC-adv Ba, p39, VlsE Bb separately) |
EUROLINE | IgM IgM IgM |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001-2 M DN 2131-3201-2 M DN 2131-5001-2 M |
||
| WESTERNBLOT |
antibodies against Borrelia afzelii IgG positive control (Westernblot/EUROLINE-WB) |
IgG |
50 x 05 |
CW 2131-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia afzelii IgM positive control (Westernblot/EUROLINE-WB) |
IgM |
50 x 05 |
CW 2131-5005 M | |||
| WESTERNBLOT |
antibodies against Borrelia burgdorferi IgG positive control |
IgG |
50 x 05 |
CW 2132-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia burgdorferi IgM positive control |
IgM |
50 x 05 |
CW 2132-5005 M | |||
| WESTERNBLOT |
antibodies against Borrelia garinii IgG positive control |
IgG |
50 x 05 |
CW 2134-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia garinii IgM positive control |
IgM |
50 x 05 |
CW 2134-5005 M | |||
| WESTERNBLOT | Anti-Borrelia EUROLINE-WB (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii plus VlsE |
IgG IgG IgG IgG |
16 x 01 240 x 01 30 x 01 48 x 01 |
DY 2131-1601-1 G DY 2131-24001-1 G DY 2131-3001-1 G DY 2131-4801-1 G |
|
| WESTERNBLOT | Anti-Borrelia EUROLINE-WB (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii plus VlsE |
IgM IgM IgM IgM |
16 x 01 240 x 01 30 x 01 48 x 01 |
DY 2131-1601-1 M DY 2131-24001-1 M DY 2131-3001-1 M DY 2131-4801-1 M |
|
| WESTERNBLOT | Anti-Borrelia afzelii-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii |
IgG IgG |
240 x 01 30 x 01 |
DY 2131-24001 G DY 2131-3001 G |
|
| WESTERNBLOT | Anti-Borrelia afzelii-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii |
IgM IgM |
240 x 01 30 x 01 |
DY 2131-24001 M DY 2131-3001 M |
|
| WESTERNBLOT | Anti-Borrelia burgdorferi-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia burgdorferi sensu stricto |
IgG |
30 x 01 |
DY 2132-3001 G | |
| WESTERNBLOT | Anti-Borrelia burgdorferi-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia burgdorferi sensu stricto |
IgM |
30 x 01 |
DY 2132-3001 M | |
| WESTERNBLOT | Anti-Borrelia garinii-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia garinii |
IgG |
30 x 01 |
DY 2134-3001 G | |
| WESTERNBLOT | Anti-Borrelia garinii-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia garinii |
IgM |
30 x 01 |
DY 2134-3001 M | |
| ChLIA | IDS Borrelia IgG | antigenic coated magnetic particles | Borrelia burgdorferi VlsE antigen |
semi-quantitative |
100 x 01 |
IS-ID62011 | |
| ChLIA | IDS Borrelia IgM | antigenic coated magnetic particles | B. afzelii, B. burgdorferi, B. garinii, B. spielmani OspC and B. burgdorferi VlsE antigen |
semi-quantitative |
100 x 01 |
IS-ID62021 | |
| ChLIA | IDS Borrelia Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID62301 | ||
| ChLIA | Anti-Borrelia ChLIA (IgG) | Antigen-coated magnetic particles |
recombinant VlsE, recombinant DbpA |
quantitative | IgG |
100 x 1 |
LI 2132-10010 G |
| ChLIA | Anti-Borrelia ChLIA (IgM) | Antigen-coated magnetic particles | recombinant OspC | quantitative | IgM |
100 x 1 |
LI 2132-10010 M |
| ChLIA | Control set Anti-Borrelia ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2132-20210 G | ||
| ChLIA | Control set Anti-Borrelia ChLIA (IgM) | 2 x 0.5 ml control 1/2 | IgM |
02 x 02 |
LR 2132-20210 M | ||
| MICROBLOT | EUROMicroblot Anti Borrelia (IgG) | IgG |
96 x 01 |
KN 2131-9601 G | |||
| MICROBLOT | EUROMicroblot Anti Borrelia (IgM) | IgM |
96 x 01 |
KN 2131-9601 M | |||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||